Clade C subtype-specific HIV-1 infections are responsible for over 48% of global HIV-1 burden. Aiming to develop a vaccine that provides heterologous protection against HIV, a research group led by investigators from the Emory Vaccine Center at Emory University recently reported a novel clade C HIV-1 vaccine.